Price
No data yet.
Social Signal Score
Revenue
$523.57M+158077.94%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jisong Cui
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,089
- Beta
- 0.39
- Country
- CN
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.66
Financials
Revenue
$523.57M+158077.9%Net Income
$104.81MEBITDA
$67.05MFree Cash Flow
$-4.15M-113.3%EPS (diluted)
$0.06Shares Outstanding (diluted)
1.76B+40.8%Operating Expenses
$388.66MCash & Debt
$7.06BReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.30B | $625.89M | $0.36 |
| 2024 | $1.01B | $-440.63M | $-0.26 |
| 2023 | $738.54M | $-631.26M | $-0.37 |
| 2022 | $625.40M | $-886.59M | $-0.60 |
| 2021 | $1.04B | $-64.55M | $-0.04 |
| 2020 | $1.36M | $-391.39M | $-0.40 |
| 2019 | $1.25M | $-2.14B | $-1.21 |
| 2018 | $1.62M | $-549.95M | $-0.44 |
| 2017 | $102.0K | $-341.73M | $-0.27 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.52
- Implied price
- $20.88
- Return from $1.55
- 68.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $10.38 — today's price is already 85.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| -2.0% | 42.1% | 47.8% | 52.6% | 57.0% | 60.9% |
| 3.0% | 49.4% | 55.3% | 60.4% | 65.0% | 69.1% |
| 8.0% | 56.6% | 62.8% | 68.2% | 73.0% | 77.3% |
| 13.0% | 63.9% | 70.4% | 76.0% | 81.0% | 85.5% |
| 18.0% | 71.1% | 77.9% | 83.8% | 89.0% | 93.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·5h ago·Positive
InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript InnoCare Pharma Limited (INCPF) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Mon, Aug 24(date passed)
Consensus estimate $-0.01 per share
Typical surprise +131.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Apr 23$0.01 vs $-0.03beat
Estimates and results for INCPF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.